Drugs / benidipine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02646397 | Feb 2016 → Dec 2017 | chronic kidney disease | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05670028 Background | Jun 2023 → Jan 2026 | ischemic stroke, vascular insufficiency disorder | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00135551 Comparator | May 2003 → May 2010 | cardiovascular disorder | Seiji Umemoto, M.D., Ph.D. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | benidipine | “The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial compared the dihydropyridine T/L-type calcium channel blocker benidipine-based therapies...” PMID 23985703 ↗ Aug 20132“To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or...” NCT05670028 ↗ |
| Known as | Benidipino | ChEMBL registry synonym — accepted as the source's own label CHEMBL2074972 ↗ |
| Action | Inhibit | “dihydropyridine T/L-type calcium channel blocker benidipine-based therapies” PMID 23985703 ↗ Aug 2013 |
| Modality | Small molecule | — CHEMBL2074972 ↗ |
| Route | Oral | “will take oral tablets of fosinopril (20 mg) plus benidipine (4/8 mg）once daily for 6 months.” NCT02646397 ↗ |